Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,465 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Humans Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on Human Skin

NCT05202834
View directory record Official record
Conditions
Healthy
Interventions
UltraClear
Device
Lead sponsor
FA Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

NCT04863287
View directory record Official record
Conditions
Lyme Disease
Interventions
2217LS, 0.9% Sodium Chloride (NaCl)
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

NCT06058390
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 19, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

NCT00229268
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

NCT06687759
View directory record Official record
Conditions
Healthy
Interventions
[14C]Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01181427
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Waukegan, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulating Human Cortical Plasticity With Transcranial Electrical Stimulation

NCT03114488
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

NCT02918929
View directory record Official record
Conditions
Presumptive NAFLD
Interventions
EDP 305, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

NCT00779259
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Theophylline 300mg, Quinine 648 mg, Theophylline 300 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Oct 19, 2026, 7:38 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Salt and TH-17 in Healthy Human Subjects

NCT02261688
View directory record Official record
Conditions
Th17 Helper Immune Cells, Autoimmunity, Salt Intake, Sodium Chloride
Interventions
Low salt diet, Low salt diet + IV normal saline, Liberal salt diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

NCT00686205
View directory record Official record
Conditions
Healthy Donors, HIV Positive
Interventions
collection of follow-up sample based on PRISM HIV O Plus result
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
17 Years and older
Enrollment
24,111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Davenport, Iowa • Kansas City, Missouri • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 19, 2026, 7:38 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans

NCT07508722
View directory record Official record
Conditions
Healthy Volunteers, no Condition, Basic Science
Interventions
Transcranial Focused Ultrasound Stimulation, Electroencephalography, Magnetic Resonance Imaging
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response Following Seasonal Influenza Vaccination

NCT03163342
View directory record Official record
Conditions
Influenza
Interventions
Licensed seasonal influenza vaccine
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

NCT05387083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Low Dose TP-05, High Dose TP-05, Placebo Comparator
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

NCT00656370
View directory record Official record
Conditions
Healthy
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

NCT04786457
View directory record Official record
Conditions
Dengue
Interventions
Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT00952263
View directory record Official record
Conditions
Healthy
Interventions
MBL-HCV1
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

NCT04628793
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07258669, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

NCT00865371
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 19, 2026, 7:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

NCT05738850
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions
ABBV-932, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 19, 2026, 7:38 PM EDT